HUT42133A - Vaccine against aids - Google Patents

Vaccine against aids

Info

Publication number
HUT42133A
HUT42133A HU864072A HU407286A HUT42133A HU T42133 A HUT42133 A HU T42133A HU 864072 A HU864072 A HU 864072A HU 407286 A HU407286 A HU 407286A HU T42133 A HUT42133 A HU T42133A
Authority
HU
Hungary
Prior art keywords
vaccine against
against aids
aids
vaccine
Prior art date
Application number
HU864072A
Other versions
HU205780B (en
Inventor
Shiu-Lok Hu
Anthony F Purchio
Linda Madisen
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US77990985A priority Critical
Priority to US84298486A priority
Priority to US90521786A priority
Application filed by Oncogen filed Critical Oncogen
Publication of HUT42133A publication Critical patent/HUT42133A/en
Publication of HU205780B publication Critical patent/HU205780B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
HU864072A 1985-09-25 1986-09-24 Process for producing recombinant viruses, proteins and vaccine against aids HU205780B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US77990985A true 1985-09-25 1985-09-25
US84298486A true 1986-03-27 1986-03-27
US90521786A true 1986-09-09 1986-09-09

Publications (2)

Publication Number Publication Date
HUT42133A true HUT42133A (en) 1987-06-29
HU205780B HU205780B (en) 1992-06-29

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
HU864072A HU205780B (en) 1985-09-25 1986-09-24 Process for producing recombinant viruses, proteins and vaccine against aids

Country Status (21)

Country Link
CN (1) CN1020752C (en)
AT (1) ATA256786A (en)
CH (1) CH676247A5 (en)
DE (1) DE3690508T1 (en)
DK (1) DK455486A (en)
ES (2) ES2002490A6 (en)
FI (1) FI863848A (en)
FR (1) FR2587720B2 (en)
GB (1) GB2181435B (en)
GR (1) GR862412B (en)
HU (1) HU205780B (en)
IE (1) IE59314B1 (en)
IL (2) IL80073D0 (en)
IT (1) IT1195829B (en)
NL (1) NL8602422A (en)
NO (1) NO863803L (en)
NZ (1) NZ217645A (en)
PT (1) PT83434B (en)
SE (4) SE8604007L (en)
WO (1) WO1987002038A1 (en)
YU (1) YU46753B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT109512T (en) * 1985-04-08 1994-08-15 Genetic Systems Corp Expression and diagnose with gag-encoded peptides which are immunologically reactive with antibodies to LAV.
EP0283327B1 (en) * 1987-01-16 1997-06-25 Institut Pasteur Peptides with the immunological properties of HIV-2
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
AT107861T (en) * 1986-09-19 1994-07-15 Oncogen Use of activated T lymphocytes for the preparation of a pharmaceutical composition for the treatment of AIDS.
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
JPS63258575A (en) * 1986-12-15 1988-10-26 Repligen Corp Recombinant hiv envelope protein produced in insect cell
FR2610632B1 (en) * 1987-02-11 1990-12-21 Pasteur Institut Peptides characteristics of human immunodeficiency retroviruses (hiv virus) applications in the diagnosis of infections with viruses and some of these, if any, to vaccination against AIDS
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399032I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
FR2620030B1 (en) * 1987-09-07 1990-03-23 Transgene Sa Expression vector of the protein of the HIV-2 virus, a causative agent of AIDS, or infected cell culture transformed by the vector obtained proteins, vaccine and antibody obtained
IL89118D0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
DE68917520D1 (en) * 1988-05-06 1994-09-22 Ferropas Ag Methods and systems for the production of HIV antigens.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biolog Expression of retrovirus gag protein eukaryotic cells
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1990012880A1 (en) * 1989-04-18 1990-11-01 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
AU5848390A (en) * 1989-06-01 1991-01-07 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US7008784B1 (en) 1989-10-13 2006-03-07 Aventis Pasteur Limited Non-infectious, non-replicating, immunogenic human immunodeficiency virus-like particles
FR2676068B1 (en) * 1991-05-02 1994-11-04 Pasteur Institut immunogenic recombinant strains of b. anthracis - immunogenic compositions containing them.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
EP1136562A3 (en) * 1991-11-08 2003-06-25 PHARMACIA & UPJOHN COMPANY Feline leukemia virus vaccines
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag From a retrovirus of the HIV group derived peptides and their use
AU5259796A (en) 1995-02-10 1996-08-27 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ES2143570T3 (en) * 1995-09-06 2000-05-16 Schablonentechnik Kufstein Ag Method for producing a screen printing stencil.
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1458360E (en) 2001-12-19 2011-07-13 Novartis Ag Pulmonary delivery of aminoglycosides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485810T2 (en) * 1983-05-27 1992-12-10 Texas A & M Univ Sys A method for producing a recombinant baculovirus expression vector.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
DE3588254T2 (en) * 1984-10-18 2008-06-26 Centre National De La Recherche Scientifique GAG antigen and its use for the detection of LAV infection, as well as in immunogenic compositions
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
DE3588134T2 (en) * 1984-12-24 1997-03-20 Genentech Inc Mergers of AIDS-related polypeptides
GB8501473D0 (en) * 1985-01-21 1985-02-20 Centre Nat Rech Scient Cloned dna sequences
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
DK171119B1 (en) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS virus envelope protein, expression vector carrying the virus coat protein, transformants transformed with the expression vector, method of producing viral coat protein, method for the detection of AIDS antibodies, Method for the determination of AIDS virus, vaccine against AIDS, antibodies to viral coat protein and employing it for preparing a the vaccine or the testnin
FR2586427B1 (en) * 1985-08-20 1988-12-09 Pasteur Institut Sequences of nucleotides and polypeptides derived from visna virus and application of diagnostic tests and the production of immunogenic compositions

Also Published As

Publication number Publication date
GB2181435A (en) 1987-04-23
SE9102976L (en) 1993-04-15
IT1195829B (en) 1988-10-27
CN86106632A (en) 1987-05-13
YU46753B (en) 1994-05-10
SE9102975D0 (en) 1991-10-14
HU205780B (en) 1992-06-29
SE8604007D0 (en) 1986-09-23
SE9102974L (en) 1993-04-15
DE3690508T1 (en) 1988-06-23
WO1987002038A1 (en) 1987-04-09
PT83434A (en) 1986-10-01
IT8667730D0 (en) 1986-09-24
IL80073D0 (en) 1986-12-31
SE9102975L (en) 1993-04-15
ES2006941A6 (en) 1989-05-16
DK455486D0 (en) 1986-09-24
DE3690508T0 (en)
FI863848A0 (en) 1986-09-24
PT83434B (en) 1988-07-29
FI863848A (en) 1987-03-26
CN1020752C (en) 1993-05-19
SE9102974D0 (en) 1991-10-14
ES2002490A6 (en) 1988-08-16
NZ217645A (en) 1991-11-26
DK455486A (en) 1987-03-26
GR862412B (en) 1987-01-23
GB8622987D0 (en) 1986-10-29
SE9102976D0 (en) 1991-10-14
IE862525L (en) 1987-03-25
ATA256786A (en) 1995-05-15
NL8602422A (en) 1987-04-16
YU165486A (en) 1989-08-31
GB2181435B (en) 1990-01-10
IL80073A (en) 1995-01-24
SE8604007L (en) 1987-03-26
CH676247A5 (en) 1990-12-28
IE59314B1 (en) 1994-02-09
FR2587720A2 (en) 1987-03-27
FR2587720B2 (en) 1995-02-10
NO863803D0 (en) 1986-09-24
FI863848D0 (en)
NO863803L (en) 1987-03-26

Similar Documents

Publication Publication Date Title
DE3664560D1 (en) Earmuff
CS391586A2 (en) Chromatograficky sloupec
IE863018L (en) Skin-moisturising microemulsion
ZA8606635B (en) Enossal implant
EP0205997A3 (en) Implant
JPS61273100A (en) Hearing aid
JPS622800A (en) Hearing aid
JPS6295098A (en) Hearing aid
JPS61213000A (en) Hearing aid
JPS61230499A (en) Hearing aid
ZA8508044B (en) Oral vaccines
IE72975B1 (en) Vaccines
EP0222835A4 (en) Oral vaccines.
CS166686A2 (en) Zpusob vyroby novych derivatu insulinu
EP0205098A3 (en) Influenza vaccine
ZA8605277B (en) Virus vaccine
YU165486A (en) Process for obtaining vaccine against aids
EP0310316A3 (en) Novel vaccine
GB2177130B (en) Toilet aids
EP0256878A3 (en) Vaccines
EP0391997A4 (en) Vaccine
GB2166349B (en) Oral vaccines
IL80927D0 (en) Immunostimulant agents
JPS6295099A (en) Hearing aid
GB2170708B (en) Vaccine system

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee